TuHURA Biosciences (HURA) Fundamental Analysis: Revenue, Earnings & Valuation

2.69 / 10

Underperform

Comprehensive analysis reveals weak fundamentals with a score of 2.7/10. Although inventory turnover ratio (47.88) and interest coverage ratio (15.51) are favorable, metrics like PB-ROE (3.16) and Asset-MV (-0.51) indicate overvaluation and asset inefficiency. Revenue and profit growth are strong year-over-year, yet absolute values remain low, and the net profit/total profit ratio of 100% suggests potential data limitations. The position is classified as selective due to mixed signals.

Analysis Checks(8/10)

Revenue-MV

Value-0.26

Score3/3

Weight30.91%

1M Return11.03%

Total operating revenue (YoY growth rate %)

Value78.62

Score3/3

Weight1.99%

1M Return0.88%

Inventory turnover ratio

Value47.88

Score2/3

Weight-2.57%

1M Return-1.23%

Profit-MV

Value0.47

Score2/3

Weight24.81%

1M Return8.99%

PB-ROE

Value3.16

Score0/3

Weight8.83%

1M Return3.36%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.51

Score2/3

Weight-2.68%

1M Return-1.25%

Operating revenue (YoY growth rate %)

Value92.79

Score2/3

Weight0.23%

1M Return0.10%

Asset-MV

Value-0.51

Score0/3

Weight16.76%

1M Return6.58%

Net profit / Total profit (%)

Value100.00

Score2/3

Weight-2.11%

1M Return-0.98%

Cash-MV

Value-0.07

Score2/3

Weight23.82%

1M Return8.80%

Is HURA undervalued or overvalued?

HURA scores 2.69/10 on fundamentals and holds a Premium valuation at present. Backed by its -226.90% ROE, 0.00% net margin, -2.52 P/E ratio, 2.28 P/B ratio, and 85.16% earnings growth, these metrics solidify its Underperform investment rating.